Add this result to my export selection Blocks: Tools and methodologies to assess integrated care in Europe (PDF) Source: European Commission (Remove filter) Published by European Commission, 01 March 2017 Measuring integration is different from measuring the performance of integrated care. This report addresses this dual challenge: on the one hand it focuses on design principles, building... Read Summary Type: Primary Research (Add filter) Type: Evidence Summaries (Add filter) Type: Quality Indicators (Remove filter)
Add this result to my export selection Avatrombopag (Doptelet®) accepted for use within NHS Scotland for treatment of severe thrombocytopenia in adult patients with chronic liver disease scheduled to undergo an invasive procedure Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 07 December 2020 Approval is based on two phase III studies which showed avatrombopag was superior to placebo for proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Mexiletine (Namuscla®) accepted for use within NHS Scotland for symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 07 December 2020 Approval of this resubmitted application is based on a short-term, phase III, crossover study; results of which showed that mexiletine significantly improved muscle stiffness compared with placebo... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Venetoclax (Venclyxto®) accepted for restricted use within NHS Scotland in combination with obinutuzumab for treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 07 December 2020 Restricted for use in patients without del (17p)/TP53 mutation who are not fit to receive fludarabine, cyclophosphamide and rituximab chemo-immunotherapy; and patients with del (17p)/TP53 mutation. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Bempedoic acid (Nilemdo®) is not recommended for use within NHS Scotland for adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 07 December 2020 In four phase III studies, the percentage reduction in LDL-C to 12-weeks was significantly larger with bempedoic acid compared with placebo; however, the company did not present sufficiently robust... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Trabectedin (Yondelis) accepted for use within NHS Scotland Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 09 November 2020 Approval is for treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Scottish Medicines Consortium completes its initial assessment of evidence for the volanesorsen (Waylivra) using ultra orphan framework (UOF) Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 09 November 2020 From 16 Nov 2020, this can be prescribed within UOF as adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome and at high risk for pancreatitis, in whom... Read Summary SPS comment Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Atezolizumab (Tecentriq®) accepted for use within NHS Scotland Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 09 November 2020 Approved for use in combination with carboplatin & etoposide for 1st line treatment of adult patients with extensive-stage small cell lung cancer. RCT reported regimen linked to modest significant... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Darolutamide (Nubeqa) is accepted for use within NHS Scotland Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 09 November 2020 Approved for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. In a phase III study in men with high... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Romosozumab (Evenity®) accepted for restricted use within NHS Scotland for treatment of severe osteoporosis in postmenopausal women at high risk of fracture. Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 09 November 2020 Approval based on RCT which demonstrated romosozumab for 12 months, followed by an oral bisphosphonate, reduced the risk of fractures compared with an oral bisphosphonate alone. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)